Edition:
United Kingdom

JCR Pharmaceuticals Co Ltd (4552.T)

4552.T on Tokyo Stock Exchange

5,230JPY
3:28am BST
Change (% chg)

¥10 (+0.19%)
Prev Close
¥5,220
Open
¥5,280
Day's High
¥5,320
Day's Low
¥5,190
Volume
56,400
Avg. Vol
133,934
52-wk High
¥7,350
52-wk Low
¥2,871

Latest Key Developments (Source: Significant Developments)

JCR Pharmaceuticals initiates phase 3 clinical trial of JR-141 for Hunter Syndrome
Thursday, 9 Aug 2018 

Aug 9 (Reuters) - JCR Pharmaceuticals Co Ltd <4552.T>:Says the company announced today the initiation of a Phase 3 clinical trial of JR-141 in Japan .JR-141 is a blood-brain-barrier (BBB)-penetrating recombinant iduronate-2-sulfatase product candidate for the treatment of patients with Hunter syndrome, to which J-Brain Cargo®, JCR’s proprietary BBB technology, is applied .  Full Article

JCR Pharmaceuticals initiates phase 2 clinical trial of JR-141 for hunter syndrome in Brazil
Friday, 29 Jun 2018 

June 29 (Reuters) - JCR Pharmaceuticals Co Ltd <4552.T>:Says it announced today the initiation of the Phase 2 clinical trial of JR-141 in Brazil.JR-141 is a blood-brain-barrier(BBB)-penetrating recombinant iduronate-2-sulfatase product candidate for the treatment of patients with Hunter syndrome, to which J-Brain Cargo®, JCR's proprietary BBB technology, has been applied .  Full Article

JCR Pharmaceuticals to recall partial sleep apnea alarm products
Monday, 25 Jun 2018 

June 25 (Reuters) - JCR Pharmaceuticals Co Ltd <4552.T> ::Says it plans to recall its partial sleep apnea alarm products, which are manufactured by the company and sold by the company and its unit, due to parts' quality problem .  Full Article

JR-131, long-acting erythropoiesis-stimulating agent, demonstrates equivalence in phase III study
Wednesday, 17 Jan 2018 

Jan 17 (Reuters) - Kissei Pharmaceutical Co Ltd <4547.T>:Says it and JCR Pharmaceuticals Co Ltd <<<4552.T>>> jointly announced positive results of the phase III study for JR-131, a proposed biosimilar to darbepoetin alfa, a long-acting erythropoiesis-stimulating agent for the treatment of renal anemia .In the Phase III study initiated in August 2016, JR-131 demonstrated equivalence in efficacy and safety compared with darbepoetin.Accordingly, in a primary endpoint of efficacy, the equivalence was verified for variations in hemoglobin concentration and the similarity with regard to the safety profile was confirmed .  Full Article

Medipal Holdings signs contract to set up JV JCR USA with JCR Pharmaceuticals
Tuesday, 19 Dec 2017 

Dec 19(Reuters) - Medipal Holdings Corp <7459.T>:Says it signed a contract to set up a JV JCR USA Inc with JCR Pharmaceuticals Co Ltd <<<4552.T>>>.Says the JV will be established in January 2018.Says the company and JCR Pharmaceuticals will hold a 35 percent stake and a 65 percent stake in the JV respectively .  Full Article

JCR Pharmaceuticals to initiate development of JR-171, new drug candidate for Hurler Syndrome using J-Brain Cargo
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - JCR Pharmaceuticals Co Ltd <4552.T>:Says it will initiate development of JR-171, new drug candidate for Hurler Syndrome using J-Brain Cargo.  Full Article

NanoCarrier and JCR conclude collaborative research agreement for drug delivery to the brain for nucleic acid medicines
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - JCR Pharmaceuticals Co Ltd <4552.T>:* Says it and NanoCarrier Co., Ltd <4571.T> conclude collaborative research agreement for drug delivery to the brain for nucleic acid medicines .* Under this agreement, Nanocarrier and JCR will integrate the unique technologies and knowledge of both companies, and aim to develop an innovative drug effectively delivered to the brain .  Full Article

BRIEF-JCR Pharmaceuticals to set up investigational new drug production center with investment of 3 bln yen

* Says it will set up an investigational new drug production center with investment of about 3 billion yen from March 2019